Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
07 nov. 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management...
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
05 nov. 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with...
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
31 oct. 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
22 oct. 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK. Principal Investigator has Been Appointed and a...
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
09 sept. 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments...
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
08 août 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites ...
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
06 août 2024 05h00 HE
|
Quoin Pharmaceuticals, Inc.
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening...
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
01 août 2024 16h10 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
27 juin 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
25 juin 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...